Clinical Trial Update: Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating whether dexamethasone-induced senescence can re-sensitize non-small cell lung cancer to PD-1 inhibitors; the study was termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• PD-1 inhibitor

Snippet

Sponsor: VA Office of Research and Development | Conditions: Non-Small Cell Lung Cancer, Immunotherapy | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-06-14